Affordable Access

Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b.

Authors
Type
Published Article
Journal
Cancer biotherapy & radiopharmaceuticals
Publication Date
Volume
20
Issue
3
Pages
280–289
Identifiers
PMID: 15989473
Source
Medline
License
Unknown

Abstract

Our clinical data are consistent with the published ECOG and Intergroup data dealing with highdose interferon in high-risk melanoma patients. The data suggest a dose-dependency on the treatment effect and, therefore, support further prospective trials comparing different dose-distribution patterns in high-dose interferon.

Statistics

Seen <100 times